Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,368JPY
28 Sep 2016
Change (% chg)

-- (--)
Prev Close
¥6,368
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
988,880
52-wk High
¥8,486
52-wk Low
¥5,366

4523.T

Chart for 4523.T

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥1,917,899.00
Shares Outstanding(Mil.): 296.57
Dividend: 70.00
Yield (%): 2.32

Financials

  4523.T Industry Sector
P/E (TTM): 26.76 36.52 36.51
EPS (TTM): 241.67 -- --
ROI: 8.62 14.40 13.85
ROE: 12.12 15.20 14.77

BRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial

* Eisai and Halozyme initiate Phase 1b/2 clinical trial with first patient dosing of eribulin in combination with PEGPH20 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 26 2016

BRIEF-Eisai, Arena announce regulatory approval of VENESPRI in Mexico

* Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI (lorcaserin HCl) in Mexico

Jul 14 2016

BRIEF-R&I affirms Eisai's rating at "A+" and stable outlook

* Says rating and Investment Information, Inc. (R&I) affirmed the rating on Eisai at "A+"

Jul 08 2016

BRIEF-U.S. FDA expands approval of Eisai's cancer drug Lenvima

* FDA Approves Eisai's Lenvima (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic therapy Source text for Eikon: (Bengaluru Newsroom: +1 646 223 8780)

May 13 2016

BRIEF-Eisai signed cooperation agreements with Pharmstandard

* Co, Pharmstandard signed cooperation agreements relating to localised production of Eisai products in Russia Source text for Eikon: Further company coverage: (Reporting by Vishal Sridhar)

Apr 05 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.